Search Results - "Jakob, John A"

NRAS mutation status is an independent prognostic factor in metastatic melanoma by Jakob, John A., Bassett, Roland L., Ng, Chaan S., Curry, Jonathan L., Joseph, Richard W., Alvarado, Gladys C., Rohlfs, Michelle L., Richard, Jessie, Gershenwald, Jeffrey E., Kim, Kevin B., Lazar, Alexander J., Hwu, Patrick, Davies, Michael A.

“…BACKGROUND: There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic…”
Get full text

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma by Bucheit, Amanda D., Syklawer, Erica, Jakob, John A., Bassett, Roland L., Curry, Jonathan L., Gershenwald, Jeffrey E., Kim, Kevin B., Hwu, Patrick, Lazar, Alexander J., Davies, Michael A.

“…BACKGROUND Hotspot mutations in BRAF and NRAS are the most common somatic events in patients with melanoma. These mutations occur at highly conserved residues,…”
Get full text

High Tumor Mutational Burden in Hepatocellular Carcinoma by Engle, Joshua A, Dibb, James T, Jakob, John A

“…Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the leading causes of cancer-related deaths worldwide. Tumor mutational…”
Get full text

Phase II study of gefitinib in patients with advanced salivary gland cancers by Jakob, John A., Kies, Merrill S., Glisson, Bonnie S., Kupferman, Michael E., Liu, Diane D., Lee, J. Jack, El-Naggar, Adel K., Gonzalez-Angulo, Ana M., Blumenschein Jr, George R.

“…Background The purpose of this study was to determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients…”
Get full text

Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy by Fang, Penny, Boehling, Nicholas S, Koay, Eugene J, Bucheit, Amanda D, Jakob, John A, Settle, Stephen H, Brown, Paul D, Davies, Michael A, Sulman, Erik P

“…Studies on melanoma brain metastases (MBM) with regard to mutational status are lacking. We investigated the outcomes of MBM in molecularly characterized…”
Get full text

Glomus Tumor of the Chest Wall With Metastases to Lung by Engle, Joshua A, Dibb, James T, Kundu, Soumajit, Jakob, John A

“…Glomus tumors are typically benign, soft tissue neoplasms composed of thermoregulatory glomus bodies. The more common varieties, such as subungual, are treated…”
Get full text

Melanoma brain metastases harboring BRAFV600K or NRAS mutations are associated with an increased local failure rate following conventional therapy by Fang, Penny, Boehling, Nicholas S., Koay, Eugene J., Bucheit, Amanda D., Jakob, John A., Settle, Stephen H., Brown, Paul D., Davies, Michael A., Sulman, Erik P.

“…Studies on melanoma brain metastases (MBM) with regard to mutational status are lacking. We investigated the outcomes of MBM in molecularly characterized…”
Get full text

Phase II study of gefitinib in patients with advanced salivary gland cancers: Phase II study of gefitinib in advanced salivary gland cancers by Jakob, John A., Kies, Merrill S., Glisson, Bonnie S., Kupferman, Michael E., Liu, Diane D., Lee, J. Jack, El-Naggar, Adel K., Gonzalez-Angulo, Ana M., Blumenschein, George R.

Get full text